Simon Woodcock
Vice President, Head of Biology RedX Pharma
Dr. Simon Woodcock joined Redx in 2016, bringing deep expertise in cancer biology from both academia and industry. He played a key role in advancing Redx’s lead oncology asset, RXC004, into the clinic and led the Pan-Raf programme that delivered JZP815 in collaboration with Jazz Pharmaceuticals. Previously, Simon worked at AstraZeneca, leading early-phase oncology projects. His academic background includes postdoctoral roles at the University of Manchester and the Paterson CRUK Institute. He holds a First-Class honours degree and a PhD in Biochemistry from the University of Manchester.
Seminars
Thursday 4th December 2025
Employing Preclinical Findings from Advanced Tumour Models to Ensure the Successful Translation of Small Molecule Therapies to the Clinic
3:30 pm
- Spotlighting lessons learned taking a small molecule from discovery to the clinic and the types of models that were used
- Nurturing relationships with CROs and academic groups to leverage cancer-associated fibroblast (CAF) models and orthotopic models for preclinical studies
- Identifying biomarkers that can predict response to Wnt, aiding in patient stratification and the design of clinical trials
